Home » Stocks » CNCE

Concert Pharmaceuticals, Inc. (CNCE)

Stock Price: $3.91 USD 0.13 (3.31%)
Updated May 13, 2021 3:21 PM EDT - Market open
Market Cap 121.62M
Revenue (ttm) 7.90M
Net Income (ttm) -76.96M
Shares Out 33.89M
EPS (ttm) -2.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $3.91
Previous Close $3.78
Change ($) 0.13
Change (%) 3.31%
Day's Open 3.81
Day's Range 3.78 - 3.92
Day's Volume 293,077
52-Week Range 3.68 - 13.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Concert (CNCE) delivered earnings and revenue surprises of -1.52% and -99.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert reports financial results for the first quarter of 2021.

1 week ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--The Company will host a conference call and webcast on May 4, 2021, to discuss its first quarter 2021 financial results and provide a busines...

2 weeks ago - Business Wire

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will present a corporate overview at the H.C. Wainwright and Oppenheimer virtual conferences in March.

2 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert reports financial results for the year ended December 31, 2020.

2 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--The Company will host a conference call and webcast on February 25, 2021, to discuss 2020 financial results and provide a business update.

2 months ago - Business Wire

The company's experimental schizophrenia drug flopped in a phase 2 study.

3 months ago - The Motley Fool

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert announced its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did not meet the primary endpoint.

3 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will present at the Stifel Healthcare Conference and participate in a fireside chat at the Jefferies London Healthcare Conference.

6 months ago - Business Wire

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast today at 8:30 a.m. ET to provide an update on the Company and discuss third quarter 2020 results.

6 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert initiated THRIVE-AA1, a Phase 3 study to evaluate the efficacy and safety of CTP-543 in adults with moderate to severe alopecia areata.

6 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert presented initial data from an ongoing long-term, open-label extension study of CTP-543 in patients with alopecia areata at EADV.

6 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast on November 5, at 8:30 AM to discuss third quarter financial results and provide a business update.

6 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Key findings of the survey show that patients with alopecia areata suffer significantly increased burden of illness.

6 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--The EADV presentation will highlight new CTP-543 data from an ongoing open label extension study in patients with moderate to severe alopecia areata.

7 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert completed enrollment in its Phase 2 trial evaluating CTP-692 as an adjunctive treatment in patients with schizophrenia.

7 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert to participate in a fireside chat with Jason Butler at The JMP Securities CNS Forum.

8 months ago - Business Wire

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Concert (CNCE) delivered earnings and revenue surprises of 39.71% and 63770.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast today at 8:30 a.m.

9 months ago - Business Wire

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert Pharmaceuticals, Inc.

9 months ago - Business Wire

Today also marked the beginning of bank earnings season, with JPMorgan beating expectations on both earnings and revenues driven by a surge in trading revenue amid the market’s volatile second quarter. ...

Other stocks mentioned: CRDF, IDN, REPH, VRTV
9 months ago - Forbes

Shortly after markets jumped in response to June's jobs report, gains were erased as a surge in coronavirus cases was reported across the country. This puts a damper on the economy's recovery.

Other stocks mentioned: ALPN, MRAM, PIXY, SGBX
10 months ago - Forbes

Concert (CNCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10 months ago - Zacks Investment Research

Is (CNCE) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) fell by 1.8% from the previous closing price.

10 months ago - Benzinga

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Other stocks mentioned: ATXI, MEIP, NERV, OCUL
11 months ago - Zacks Investment Research

Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Concert (CNCE) delivered earnings and revenue surprises of 5.41% and -65.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Concert (CNCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

1 year ago - Zacks Investment Research

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Concert Pharmaceuticals, Inc (CNCE) CEO Roger Tung on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Concert (CNCE) delivered earnings and revenue surprises of 15.29% and -97.14%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Shares fall hard after a late-stage trial comes up short.

1 year ago - The Motley Fool

Concert announced that it had achieved the primary endpoint in the phase 2 study using CTP-543 to treat patients with alopecia areata.

1 year ago - Seeking Alpha

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Concert (CNCE) delivered earnings and revenue surprises of 15.22% and -83.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.

1 year ago - Zacks Investment Research

Shares at one point tripled shortly after my original article but have lost around half their value since my last update piece.

1 year ago - Seeking Alpha

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

There is an old drug that might have lots of new tricks in its sleeve.

2 years ago - Seeking Alpha

Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.

2 years ago - Zacks Investment Research

Shares of Concert Pharmaceuticals Inc. took a sharp afternoon dive Monday, after the biopharmaceutical company said the patent trial and appeal board found that the claims of the patent on its alopecia ...

2 years ago - Market Watch

About CNCE

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquarter... [Read more...]

Industry
Biotechnology
IPO Date
Feb 13, 2014
CEO
Roger Tung
Employees
71
Stock Exchange
NASDAQ
Ticker Symbol
CNCE
Full Company Profile

Financial Performance

In 2020, CNCE's revenue was $7.90 million, an increase of 633.70% compared to the previous year's $1.08 million. Losses were -$74.77 million, -4.35% less than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for CNCE stock is "Strong Buy." The 12-month stock price forecast is 15.00, which is an increase of 284.12% from the latest price.

Price Target
$15.00
(284.12% upside)
Analyst Consensus: Strong Buy